LAUSR

DOI: 10.1097/TXD.0000000000001122 Received 6 October 2020. Revision received 8 December 2020. Accepted 18 December 2020. 1 Department of Cardiology, Hospital de Santa Cruz, Centro Hospitalar Lisboa Ocidental, Carnaxide, Portugal. 2 Department of Nephrology, Hospital de Santa Cruz, Centro Hospitalar Lisboa Ocidental, Carnaxide, Portugal. 3 Department of Endocrinology, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal. 4 Department of Cardiothoracic Surgery, Hospital de Santa Cruz, Centro Hospitalar Lisboa Ocidental, Carnaxide, Portugal. The authors declare no funding or conflicts of interest. S.M. wrote the first draft of this article. B.M.L.R., G.J.L.C., C.B., C.S., and C.A. incorporated feedback in subsequent drafts and revisions. B.M.L.R., G.J.L.C., C.B., C.S., A.T., A.W., J.S.D., C.A., M.M., and J.P.N. contributed to revisions and reviewed the final draft. S.M. composed the figures and submitted the final version of this article on behalf of all the authors. The patient has verbally consented to the publication of his medical case in a Medical Journal. Members of the Transplant Team (S.M., B.M.L.R., G.J.L.C., C.B., C.S., and C.A.) obtained the informed consent. This investigation was conducted in accordance with the World Medical Association Declaration of Helsinki (seventh revision, Fortaleza, 2013) and the Declaration of Istanbul (2008). Furthermore, the authors declare that the figure within this article (highrisk markers for rapid progression in advanced heart failure patients) does not allow the identification of the patient. Dates were not specified to comply with patient confidentiality. This case report was exempt from ethics board approval. Correspondence: Sérgio Maltês, MD, Department of Cardiology, Hospital de Santa Cruz, Centro Hospitalar Lisboa Ocidental, Av. Prof. Dr. Reinaldo dos Santos, 2790-134 Carnaxide, Lisboa, Portugal. ([email protected]).